FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226475746> ?p ?o ?g. }

• W4226475746 endingPage "97" @default.
• W4226475746 startingPage "91" @default.
• W4226475746 abstract "Dyslipidemia is recognized as one of the major risk factors for cardiovascular diseases. This retrospective observational study was aimed to assess the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in dyslipidemic patients with a lipid profile not well controlled by maximally tolerated statin therapy or intolerant to these lipid-lowering drugs. We enrolled 151 patients, of whom, 119 were taking evolocumab and 32 alirocumab.Total cholesterol significantly decreased progressively until the fourth year; after 4 years there was a significant reduction (-125.5 mg/dl, -51.5%, P < 0.0001 vs baseline, and P < 0.05 vs 1 year and P < 0.05 vs 2 years) and -2.8 mg/dl (-2.3%) compared with the third year. Low-density lipoprotein-cholesterol (LDL-C) also decreased significantly until the fourth year. After 3 years, there was a significant reduction (-117.8 mg/dl, -71.5%, P < 0.0001 vs baseline, and P < 0.05 vs 1 year) and -13.9 mg/dl (-22.8%) compared with the second year; after 4 years there was a significant reduction (-121.4 mg/dl, -73.7%, P < 0.0001 vs baseline, and P < 0.05 vs 1 year and P < 0.05 vs 2 years) and -3.6 mg/dl (-7.7%) compared with the third year. High-density lipoprotein-cholesterol increased significantly only during the fourth year of detection. After 3 years, there was a nonsignificant increase (4.9 mg/dl, 10.0%, P = 0.061 vs baseline) and 1.6 mg/dl (3.1%) compared with the second year; after 4 years, there was a significant increase (5.2 mg/dl, 10.6%, P < 0.05 vs baseline) and 0.3 mg/dl (0.6%) compared with the third year. The value of Tg was significantly reduced progressively until the second year and then stabilized in the third and fourth years. After 3 years, the value of Tg stabilized (-48.6 mg/dl, -32.4%, P < 0.01 vs baseline, and P < 0.05 vs 1 year) and -4.8 mg/dl (-4.5%) compared with the second year; after 4 years (-46.4 mg/dl, -31.0%, P < 0.01 vs baseline, and P < 0.05 vs 1 year) there was a slight and nonsignificant increase of 2.2 mg/dl (2.2%) compared with the third year. Regarding adverse events, both drugs were well tolerated.We showed that PCSK9 inhibitors are well tolerated and provide long-term significant LDL-C lowering in individuals with hyperlipidemia." @default.
• W4226475746 created "2022-05-05" @default.
• W4226475746 creator A5004495176 @default.
• W4226475746 creator A5008140156 @default.
• W4226475746 creator A5010271228 @default.
• W4226475746 creator A5011551760 @default.
• W4226475746 creator A5018537746 @default.
• W4226475746 creator A5021841408 @default.
• W4226475746 creator A5026295154 @default.
• W4226475746 creator A5027401178 @default.
• W4226475746 creator A5036458125 @default.
• W4226475746 creator A5045550536 @default.
• W4226475746 creator A5049217502 @default.
• W4226475746 creator A5070800403 @default.
• W4226475746 creator A5070809873 @default.
• W4226475746 creator A5087250296 @default.
• W4226475746 date "2021-10-22" @default.
• W4226475746 modified "2023-10-17" @default.
• W4226475746 title "Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients: a real world prescription" @default.
• W4226475746 cites W1423581981 @default.
• W4226475746 cites W1520609538 @default.
• W4226475746 cites W1816597323 @default.
• W4226475746 cites W1985747185 @default.
• W4226475746 cites W2001328643 @default.
• W4226475746 cites W2116404316 @default.
• W4226475746 cites W2135503869 @default.
• W4226475746 cites W2141898196 @default.
• W4226475746 cites W2156299572 @default.
• W4226475746 cites W2337193712 @default.
• W4226475746 cites W2511420668 @default.
• W4226475746 cites W2554832534 @default.
• W4226475746 cites W2596179513 @default.
• W4226475746 cites W2596236174 @default.
• W4226475746 cites W2766232664 @default.
• W4226475746 cites W2899997727 @default.
• W4226475746 cites W3040745624 @default.
• W4226475746 cites W3081393036 @default.
• W4226475746 cites W3098063240 @default.
• W4226475746 cites W3134344235 @default.
• W4226475746 cites W3183857127 @default.
• W4226475746 cites W4238251256 @default.
• W4226475746 cites W4379439872 @default.
• W4226475746 cites W630612001 @default.
• W4226475746 doi "https://doi.org/10.2459/jcm.0000000000001237" @default.
• W4226475746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34690259" @default.
• W4226475746 hasPublicationYear "2021" @default.
• W4226475746 type Work @default.
• W4226475746 citedByCount "3" @default.
• W4226475746 countsByYear W42264757462022 @default.
• W4226475746 countsByYear W42264757462023 @default.
• W4226475746 crossrefType "journal-article" @default.
• W4226475746 hasAuthorship W4226475746A5004495176 @default.
• W4226475746 hasAuthorship W4226475746A5008140156 @default.
• W4226475746 hasAuthorship W4226475746A5010271228 @default.
• W4226475746 hasAuthorship W4226475746A5011551760 @default.
• W4226475746 hasAuthorship W4226475746A5018537746 @default.
• W4226475746 hasAuthorship W4226475746A5021841408 @default.
• W4226475746 hasAuthorship W4226475746A5026295154 @default.
• W4226475746 hasAuthorship W4226475746A5027401178 @default.
• W4226475746 hasAuthorship W4226475746A5036458125 @default.
• W4226475746 hasAuthorship W4226475746A5045550536 @default.
• W4226475746 hasAuthorship W4226475746A5049217502 @default.
• W4226475746 hasAuthorship W4226475746A5070800403 @default.
• W4226475746 hasAuthorship W4226475746A5070809873 @default.
• W4226475746 hasAuthorship W4226475746A5087250296 @default.
• W4226475746 hasConcept C126322002 @default.
• W4226475746 hasConcept C134018914 @default.
• W4226475746 hasConcept C2776839432 @default.
• W4226475746 hasConcept C2778096610 @default.
• W4226475746 hasConcept C2778114629 @default.
• W4226475746 hasConcept C2778163477 @default.
• W4226475746 hasConcept C2778270857 @default.
• W4226475746 hasConcept C2778849439 @default.
• W4226475746 hasConcept C2779134260 @default.
• W4226475746 hasConcept C2780072125 @default.
• W4226475746 hasConcept C2780745583 @default.
• W4226475746 hasConcept C2780902209 @default.
• W4226475746 hasConcept C2780948078 @default.
• W4226475746 hasConcept C43554185 @default.
• W4226475746 hasConcept C71924100 @default.
• W4226475746 hasConcept C90924648 @default.
• W4226475746 hasConceptScore W4226475746C126322002 @default.
• W4226475746 hasConceptScore W4226475746C134018914 @default.
• W4226475746 hasConceptScore W4226475746C2776839432 @default.
• W4226475746 hasConceptScore W4226475746C2778096610 @default.
• W4226475746 hasConceptScore W4226475746C2778114629 @default.
• W4226475746 hasConceptScore W4226475746C2778163477 @default.
• W4226475746 hasConceptScore W4226475746C2778270857 @default.
• W4226475746 hasConceptScore W4226475746C2778849439 @default.
• W4226475746 hasConceptScore W4226475746C2779134260 @default.
• W4226475746 hasConceptScore W4226475746C2780072125 @default.
• W4226475746 hasConceptScore W4226475746C2780745583 @default.
• W4226475746 hasConceptScore W4226475746C2780902209 @default.
• W4226475746 hasConceptScore W4226475746C2780948078 @default.
• W4226475746 hasConceptScore W4226475746C43554185 @default.
• W4226475746 hasConceptScore W4226475746C71924100 @default.
• W4226475746 hasConceptScore W4226475746C90924648 @default.
• W4226475746 hasIssue "2" @default.

• next